The Cost‐Effectiveness of Rotavirus Vaccination in Malawi
Open Access
- 1 September 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 202 (S1) , S108-S115
- https://doi.org/10.1086/653578
Abstract
Background. Rotarix (GlaxoSmithKline), a newly licensed rotavirus vaccine requiring 2 doses, may have the potential to save hundreds of thousands ofKeywords
This publication has 23 references indexed in Scilit:
- Epidemiology of rotavirus-associated hospital admissions in the province of Ferrara, ItalyEuropean Journal of Pediatrics, 2009
- Cost-effectiveness of three different vaccination strategies against measles in Zambian childrenVaccine, 2004
- Global Illness and Deaths Caused by Rotavirus Disease in ChildrenEmerging Infectious Diseases, 2003
- The World Health Report 2002 - Reducing Risks, Promoting Healthy LifePublished by Taylor & Francis ,2003
- Effect of concomitant HIV infection on presentation and outcome of rotavirus gastroenteritis in Malawian childrenThe Lancet, 2001
- Discounting for health effects in cost–benefit and cost‐effectiveness analysisHealth Economics, 2001
- Epidemiology and predictors of infant morbidity in rural MalawiPaediatric and Perinatal Epidemiology, 2000
- Discounting: technical issues in economic evaluations of vaccinationVaccine, 1999
- Rotavirus Infection in Infants as Protection against Subsequent InfectionsNew England Journal of Medicine, 1996
- Global progress in the control of diarrheal diseasesThe Pediatric Infectious Disease Journal, 1990